FR2859910B1 - USE OF 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - Google Patents

USE OF 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Info

Publication number
FR2859910B1
FR2859910B1 FR0410073A FR0410073A FR2859910B1 FR 2859910 B1 FR2859910 B1 FR 2859910B1 FR 0410073 A FR0410073 A FR 0410073A FR 0410073 A FR0410073 A FR 0410073A FR 2859910 B1 FR2859910 B1 FR 2859910B1
Authority
FR
France
Prior art keywords
bishomo
cholecalciferol
epi
diene
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0410073A
Other languages
French (fr)
Other versions
FR2859910A1 (en
Inventor
Luciano Adorini
Enrico Colli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell SpA filed Critical Bioxell SpA
Publication of FR2859910A1 publication Critical patent/FR2859910A1/en
Application granted granted Critical
Publication of FR2859910B1 publication Critical patent/FR2859910B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR0410073A 2003-09-24 2004-09-23 USE OF 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA Expired - Fee Related FR2859910B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (2)

Publication Number Publication Date
FR2859910A1 FR2859910A1 (en) 2005-03-25
FR2859910B1 true FR2859910B1 (en) 2006-04-28

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0410073A Expired - Fee Related FR2859910B1 (en) 2003-09-24 2004-09-23 USE OF 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Country Status (12)

Country Link
EP (1) EP1673096A1 (en)
JP (2) JP2007506699A (en)
CN (1) CN100488511C (en)
BE (1) BE1016292A3 (en)
BR (1) BRPI0404050A (en)
CH (1) CH698144B1 (en)
EA (1) EA010240B1 (en)
FR (1) FR2859910B1 (en)
HK (1) HK1085373A1 (en)
NL (1) NL1027109C2 (en)
NZ (1) NZ535531A (en)
WO (1) WO2005027923A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100965205B1 (en) * 2004-10-05 2010-06-24 깃세이 야쿠힌 고교 가부시키가이샤 Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
PT1806136E (en) * 2004-10-06 2012-03-08 Kissei Pharmaceutical Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (en) * 2017-03-20 2018-09-21 Pierre Fabre Medicament USE OF COPAIFERA OLEORESIN IN THE PATHOLOGIES OF THE PROSTATE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds

Also Published As

Publication number Publication date
CH698144B1 (en) 2009-05-29
JP2009035559A (en) 2009-02-19
JP2007506699A (en) 2007-03-22
NL1027109C2 (en) 2005-05-03
WO2005027923A1 (en) 2005-03-31
BRPI0404050A (en) 2005-06-14
NZ535531A (en) 2006-03-31
CN100488511C (en) 2009-05-20
EP1673096A1 (en) 2006-06-28
CN1615891A (en) 2005-05-18
NL1027109A1 (en) 2005-03-29
BE1016292A3 (en) 2006-07-04
EA200401100A1 (en) 2005-04-28
FR2859910A1 (en) 2005-03-25
EA010240B1 (en) 2008-06-30
HK1085373A1 (en) 2006-08-25

Similar Documents

Publication Publication Date Title
DE60023982D1 (en) System for the treatment of benign prostatic hyperplasia
DE60022692D1 (en) (S, S) reboxetine for the treatment of migraine headache
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
DK1294644T3 (en) Water Treatment Compositions
NO20034877D0 (en) Use of biphosphonates in the treatment of bone metastasis associated with prostate cancer
DK1112106T3 (en) Serotonergic 5HT2 agonists for the treatment of glaucoma
NO20034166L (en) Molecular conjugates for use in the treatment of cancer
NO20026008D0 (en) Procedure for the treatment of cardiovascular diseases
MA25847A1 (en) COMPOSITION FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION.
DK1176964T3 (en) Use of ET743 for the treatment of cancer
DK1764111T3 (en) Vaginally administered anti-dysrhythmia agents for the treatment of uterine dysrhythmia
DK1392318T3 (en) 15-keto-prostaglandins for the treatment of drug-induced constipation
NO20034473D0 (en) Use of selective cox-2 inhibitors in the treatment of urinary incontinence
DE60220297D1 (en) LAUNDRY TREATMENT AGENT
FR2859910B1 (en) USE OF 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
DE50105735D1 (en) CHLOROZAZAZONE FOR THE TREATMENT OF PSORIASIS
DE50205466D1 (en) SUBSTITUTED 2,5-DIAMIDOINDOLE AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
MA27202A1 (en) COMPOSITION FOR TREATING TISSUES COMPRISING AN AGENT FOR IMPROVING THE APPEARANCE OF THE RINSING SOLUTION
NO20030978L (en) Treatment of urinary dysfunction
MA25852A1 (en) METHOD FOR THE TREATMENT OF INFLAMMATION.
DK1268482T3 (en) Pyranoindoles for the treatment of glaucoma
ATE250580T1 (en) SUBSTITUTED PYRIDINO-ARYLPIPERAZINE FOR THE TREATMENT OF BENIGGER PROSTATE HYPERPLASIA
DZ3320A1 (en) Complex comprising eletriptane and sulphobutylether-cyclodextrin for the treatment of migraine
EP1372639A4 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
DE60133596D1 (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110531